BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/11/2022 5:53:38 AM | Browse: 411 | Download: 871
 |
Received |
|
2022-02-17 09:33 |
|
Peer-Review Started |
|
2022-02-17 09:33 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-04-17 22:44 |
|
Revised |
|
2022-04-26 13:59 |
|
Second Decision |
|
2022-06-08 03:12 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-06-17 22:34 |
|
Articles in Press |
|
2022-06-17 22:34 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-07-05 13:37 |
|
Publish the Manuscript Online |
|
2022-07-11 05:53 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Ophthalmology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Efficacy and mechanism of anti-vascular endothelial growth factor drugs for diabetic macular edema patients
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yun-Fei Li, Qian Ren, Chao-Hui Sun, Li Li, Hai-Dong Lian, Rui-Xue Sun, Xian Su and Hua Yu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Qian Ren, MD, Associate Chief Physician, Department of Ophthalmology, Shijiazhuang City People’s Hospital, No. 365 Jianhua South Street, Yuhua District, Shijiazhuang 050031, Hebei Province, China. qr31535@163.com |
| Key Words |
Diabetic macular edema; Vascular endothelial growth factor; Compaq; Ranibizumab; Optimally correct vision; Diabetes |
| Core Tip |
The main pathological feature of diabetic macular edema (DME) is abnormal neovascularization throughout the retinal pigment epithelium. New vessels develop rapidly and are fragile, thus resulting to rupture and retinal detachment, macular edema, impaired, vision and blind spots. Without effective treatment, vision declines rapidly, causing irreversible impairment. Compaq has a strong affinity with vascular endothelial growth factor (VEGF) receptors, and as a novel VEGF biological agent, it has a relatively strong inhibition of vascular growth in ocular lesions. Our study investigated the effect and mechanism of anti-VEGF drugs in DME patients to improve clinical DME treatment. |
| Publish Date |
2022-07-11 05:53 |
| Citation |
Li YF, Ren Q, Sun CH, Li L, Lian HD, Sun RX, Su X, Yu H. Efficacy and mechanism of anti-vascular endothelial growth factor drugs for diabetic macular edema patients. World J Diabetes 2022; 13(7): 532-542 |
| URL |
https://www.wjgnet.com/1948-9358/full/v13/i7/532.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v13.i7.532 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
